Evan Seigerman
Stock Analyst at BMO Capital
(3.92)
# 476
Out of 4,814 analysts
140
Total ratings
52.17%
Success rate
7.76%
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Market Perform | $156 → $139 | $118.61 | +17.19% | 26 | Feb 13, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $110 → $115 | $104.53 | +10.02% | 15 | Feb 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $566 → $520 | $489.10 | +6.32% | 14 | Dec 20, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $57 → $61 | $49.23 | +23.92% | 11 | Nov 12, 2024 | |
| INCY Incyte | Reiterates: Underperform | $48 → $52 | $58.22 | -10.68% | 12 | Oct 30, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $128 → $114 | $100.10 | +13.89% | 14 | Oct 17, 2024 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $1,001 → $1,101 | $839.90 | +31.09% | 8 | Aug 9, 2024 | |
| IRON Disc Medicine | Reiterates: Outperform | $50 → $70 | $42.24 | +65.72% | 5 | Jun 17, 2024 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $21.69 | +84.46% | 1 | Feb 28, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $40 | $7.96 | +402.51% | 1 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $757 → $788 | $563.16 | +39.92% | 17 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $8 → $2.5 | $2.02 | +23.76% | 2 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $263 → $243 | $277.29 | -12.37% | 6 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $4.55 | +163.74% | 2 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $22.15 | +170.94% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $27 | $1.12 | +2,310.71% | 2 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $30 | $1.27 | +2,262.20% | 3 | May 12, 2020 |
Biogen
Feb 13, 2025
Maintains: Market Perform
Price Target: $156 → $139
Current: $118.61
Upside: +17.19%
Gilead Sciences
Feb 12, 2025
Maintains: Outperform
Price Target: $110 → $115
Current: $104.53
Upside: +10.02%
Vertex Pharmaceuticals
Dec 20, 2024
Maintains: Outperform
Price Target: $566 → $520
Current: $489.10
Upside: +6.32%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Market Perform
Price Target: $57 → $61
Current: $49.23
Upside: +23.92%
Incyte
Oct 30, 2024
Reiterates: Underperform
Price Target: $48 → $52
Current: $58.22
Upside: -10.68%
Neurocrine Biosciences
Oct 17, 2024
Maintains: Market Perform
Price Target: $128 → $114
Current: $100.10
Upside: +13.89%
Eli Lilly and Company
Aug 9, 2024
Maintains: Outperform
Price Target: $1,001 → $1,101
Current: $839.90
Upside: +31.09%
Disc Medicine
Jun 17, 2024
Reiterates: Outperform
Price Target: $50 → $70
Current: $42.24
Upside: +65.72%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $21.69
Upside: +84.46%
Replimune Group
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $7.96
Upside: +402.51%
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $563.16
Upside: +39.92%
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $2.02
Upside: +23.76%
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $277.29
Upside: -12.37%
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $4.55
Upside: +163.74%
Nov 19, 2021
Initiates: Outperform
Price Target: $60
Current: $22.15
Upside: +170.94%
Aug 13, 2021
Maintains: Outperform
Price Target: $30 → $27
Current: $1.12
Upside: +2,310.71%
May 12, 2020
Maintains: Outperform
Price Target: $13 → $30
Current: $1.27
Upside: +2,262.20%